ZyVersa Therapeutics Statistics
Total Valuation
ZVSA has a market cap or net worth of $4.45 million. The enterprise value is $1.32 million.
| Market Cap | 4.45M |
| Enterprise Value | 1.32M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ZVSA has 7.59 million shares outstanding. The number of shares has increased by 212.03% in one year.
| Shares Outstanding | 7.59M |
| Shares Change (YoY) | +212.03% |
| Shares Change (QoQ) | +10.16% |
| Owned by Insiders (%) | 0.83% |
| Owned by Institutions (%) | 2.65% |
| Float | 7.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.40 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.33, with a Debt / Equity ratio of 0.00.
| Current Ratio | 0.33 |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 235,786.07 |
Financial Efficiency
Return on equity (ROE) is -287.30% and return on invested capital (ROIC) is -972.23%.
| Return on Equity (ROE) | -287.30% |
| Return on Assets (ROA) | -210.50% |
| Return on Capital (ROIC) | -972.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$15.18M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -9.46M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.04% in the last 52 weeks. The beta is 0.58, so ZVSA's price volatility has been lower than the market average.
| Beta (1Y) | 0.58 |
| 52-Week Price Change | -99.04% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 2.95 |
| Relative Strength Index (RSI) | 35.07 |
| Average Volume (30 Days) | 2,510,164 |
Short Selling Information
The latest short interest is 580,591, so 7.64% of the outstanding shares have been sold short.
| Short Interest | 580,591 |
| Short Previous Month | 645,991 |
| Short % of Shares Out | 7.64% |
| Short % of Float | 7.75% |
| Short Ratio (days to cover) | 0.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -107.75M |
| Pretax Income | -107.75M |
| Net Income | -106.25M |
| EBITDA | -107.74M |
| EBIT | -107.75M |
| Earnings Per Share (EPS) | -$108.97 |
Balance Sheet
The company has $3.14 million in cash and $8,656 in debt, giving a net cash position of $3.13 million or $0.41 per share.
| Cash & Cash Equivalents | 3.14M |
| Total Debt | 8,656 |
| Net Cash | 3.13M |
| Net Cash Per Share | $0.41 |
| Equity / Book Value | 11.07M |
| Book Value Per Share | 1.46 |
| Working Capital | -6.84M |
Cash Flow
| Operating Cash Flow | -8.72M |
| Capital Expenditures | n/a |
| Free Cash Flow | -8.72M |
| FCF Per Share | -$8.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZVSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -212.03% |
| Shareholder Yield | -212.03% |
| Earnings Yield | -2,387.24% |
| FCF Yield | -195.95% |
Analyst Forecast
The average price target for ZVSA is $12.00, which is 1,947.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 1,947.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -23.12% |
Stock Splits
The last stock split was on December 5, 2023. It was a reverse split with a ratio of 1:35.
| Last Split Date | Dec 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:35 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |